Apex Biotechnology Corp (1733) - Net Assets
Based on the latest financial reports, Apex Biotechnology Corp (1733) has net assets worth NT$1.81 Billion TWD (≈ $57.17 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$2.31 Billion ≈ $72.76 Million USD) and total liabilities (NT$494.69 Million ≈ $15.59 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 1733 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.81 Billion |
| % of Total Assets | 78.58% |
| Annual Growth Rate | 4.36% |
| 5-Year Change | 10.82% |
| 10-Year Change | -5.47% |
| Growth Volatility | 9.08 |
Apex Biotechnology Corp - Net Assets Trend (2002–2024)
This chart illustrates how Apex Biotechnology Corp's net assets have evolved over time, based on quarterly financial data. Also explore Apex Biotechnology Corp total assets for the complete picture of this company's asset base.
Annual Net Assets for Apex Biotechnology Corp (2002–2024)
The table below shows the annual net assets of Apex Biotechnology Corp from 2002 to 2024. For live valuation and market cap data, see market value of Apex Biotechnology Corp.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.82 Billion ≈ $57.47 Million |
+1.52% |
| 2023-12-31 | NT$1.80 Billion ≈ $56.61 Million |
-1.15% |
| 2022-12-31 | NT$1.82 Billion ≈ $57.27 Million |
+3.67% |
| 2021-12-31 | NT$1.75 Billion ≈ $55.25 Million |
+6.52% |
| 2020-12-31 | NT$1.65 Billion ≈ $51.86 Million |
-1.83% |
| 2019-12-31 | NT$1.68 Billion ≈ $52.83 Million |
+2.00% |
| 2018-12-31 | NT$1.64 Billion ≈ $51.79 Million |
-1.26% |
| 2017-12-31 | NT$1.66 Billion ≈ $52.45 Million |
-3.89% |
| 2016-12-31 | NT$1.73 Billion ≈ $54.58 Million |
-10.23% |
| 2015-12-31 | NT$1.93 Billion ≈ $60.80 Million |
+3.40% |
| 2014-12-31 | NT$1.87 Billion ≈ $58.80 Million |
-2.82% |
| 2013-12-31 | NT$1.92 Billion ≈ $60.51 Million |
-4.59% |
| 2012-12-31 | NT$2.01 Billion ≈ $63.41 Million |
+15.00% |
| 2011-12-31 | NT$1.75 Billion ≈ $55.14 Million |
+7.39% |
| 2010-12-31 | NT$1.63 Billion ≈ $51.35 Million |
+10.78% |
| 2009-12-31 | NT$1.47 Billion ≈ $46.35 Million |
+16.38% |
| 2008-12-31 | NT$1.26 Billion ≈ $39.83 Million |
-6.30% |
| 2007-12-31 | NT$1.35 Billion ≈ $42.50 Million |
+22.36% |
| 2006-12-31 | NT$1.10 Billion ≈ $34.74 Million |
+22.93% |
| 2005-12-31 | NT$896.93 Million ≈ $28.26 Million |
+3.58% |
| 2004-12-31 | NT$865.91 Million ≈ $27.28 Million |
+2.79% |
| 2003-12-31 | NT$842.42 Million ≈ $26.54 Million |
+18.19% |
| 2002-12-31 | NT$712.76 Million ≈ $22.46 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Apex Biotechnology Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 114.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$215.96 Million | 11.84% |
| Common Stock | NT$999.50 Million | 54.81% |
| Other Comprehensive Income | NT$579.97 Million | 31.80% |
| Other Components | NT$28.16 Million | 1.54% |
| Total Equity | NT$1.82 Billion | 100.00% |
Apex Biotechnology Corp Competitors by Market Cap
The table below lists competitors of Apex Biotechnology Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pinar Sut Mamulleri Sanayi AS
IS:PNSUT
|
$89.93 Million |
|
QES Group Bhd
KLSE:0196
|
$89.94 Million |
|
Taiwan Takisawa Technology Co Ltd
TWO:6609
|
$89.94 Million |
|
Kluang Rubber Company Malaya
KLSE:2453
|
$89.95 Million |
|
KAISA GROUP HLDGS
F:KG5
|
$89.89 Million |
|
Shine Justice Ltd
AU:SHJ
|
$89.89 Million |
|
Kyung Dong Pharmaceutical Co. Ltd
KQ:011040
|
$89.89 Million |
|
Bathurst Resources Ltd
F:B0R
|
$89.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Apex Biotechnology Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,796,434,000 to 1,823,597,000, a change of 27,163,000 (1.5%).
- Net income of 127,998,000 contributed positively to equity growth.
- Dividend payments of 109,945,000 reduced retained earnings.
- Other comprehensive income increased equity by 13,864,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$128.00 Million | +7.02% |
| Dividends Paid | NT$109.94 Million | -6.03% |
| Other Comprehensive Income | NT$13.86 Million | +0.76% |
| Other Changes | NT$-4.75 Million | -0.26% |
| Total Change | NT$- | 1.51% |
Book Value vs Market Value Analysis
This analysis compares Apex Biotechnology Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.57x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.87x to 1.57x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$15.28 | NT$28.55 | x |
| 2010-12-31 | NT$16.90 | NT$28.55 | x |
| 2011-12-31 | NT$18.19 | NT$28.55 | x |
| 2012-12-31 | NT$20.21 | NT$28.55 | x |
| 2013-12-31 | NT$18.37 | NT$28.55 | x |
| 2014-12-31 | NT$17.82 | NT$28.55 | x |
| 2015-12-31 | NT$18.11 | NT$28.55 | x |
| 2016-12-31 | NT$17.37 | NT$28.55 | x |
| 2017-12-31 | NT$15.42 | NT$28.55 | x |
| 2018-12-31 | NT$14.65 | NT$28.55 | x |
| 2019-12-31 | NT$14.83 | NT$28.55 | x |
| 2020-12-31 | NT$14.56 | NT$28.55 | x |
| 2021-12-31 | NT$16.59 | NT$28.55 | x |
| 2022-12-31 | NT$18.05 | NT$28.55 | x |
| 2023-12-31 | NT$17.91 | NT$28.55 | x |
| 2024-12-31 | NT$18.16 | NT$28.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Apex Biotechnology Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.02%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.91%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 1.33x
- Recent ROE (7.02%) is below the historical average (15.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 14.13% | 22.55% | 0.56x | 1.13x | NT$29.46 Million |
| 2003 | 19.31% | 26.77% | 0.63x | 1.15x | NT$77.92 Million |
| 2004 | 19.11% | 26.69% | 0.62x | 1.15x | NT$78.89 Million |
| 2006 | 27.64% | 29.54% | 0.79x | 1.18x | NT$194.29 Million |
| 2007 | 29.87% | 35.58% | 0.73x | 1.15x | NT$267.77 Million |
| 2008 | 22.49% | 23.84% | 0.80x | 1.17x | NT$157.88 Million |
| 2009 | 22.19% | 22.69% | 0.81x | 1.21x | NT$179.36 Million |
| 2010 | 27.85% | 25.94% | 0.90x | 1.20x | NT$290.97 Million |
| 2011 | 30.09% | 28.07% | 0.88x | 1.22x | NT$351.59 Million |
| 2012 | 25.98% | 25.80% | 0.74x | 1.37x | NT$321.54 Million |
| 2013 | 19.34% | 20.29% | 0.67x | 1.42x | NT$179.25 Million |
| 2014 | 14.64% | 15.28% | 0.68x | 1.42x | NT$86.61 Million |
| 2015 | 13.57% | 14.17% | 0.69x | 1.40x | NT$68.91 Million |
| 2016 | 0.18% | 0.18% | 0.71x | 1.44x | NT$-170.03 Million |
| 2017 | 5.14% | 4.77% | 0.66x | 1.62x | NT$-80.85 Million |
| 2018 | 5.79% | 4.65% | 0.80x | 1.55x | NT$-69.08 Million |
| 2019 | 6.79% | 5.18% | 0.78x | 1.68x | NT$-53.72 Million |
| 2020 | 5.76% | 4.73% | 0.76x | 1.61x | NT$-69.74 Million |
| 2021 | 11.54% | 9.49% | 0.80x | 1.52x | NT$26.95 Million |
| 2022 | 10.00% | 8.10% | 0.89x | 1.38x | NT$52.60K |
| 2023 | 6.45% | 6.91% | 0.73x | 1.28x | NT$-63.86 Million |
| 2024 | 7.02% | 6.91% | 0.77x | 1.33x | NT$-54.36 Million |
Industry Comparison
This section compares Apex Biotechnology Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,830,842,000
- Average return on equity (ROE) among peers: -0.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Apex Biotechnology Corp (1733) | NT$1.81 Billion | 14.13% | 0.27x | $89.90 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $3.42 Billion | 0.26% | 0.72x | $188.76 Million |
| Panion & BF Biotech Inc (1760) | $2.01 Billion | 9.08% | 0.54x | $184.23 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $3.36 Billion | 1.58% | 0.42x | $68.46 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $996.24 Million | 6.00% | 0.56x | $99.61 Million |
| Level Biotechnology (3118) | $522.28 Million | 13.08% | 0.40x | $34.35 Million |
| GenMont Biotech Inc (3164) | $290.14 Million | -2.84% | 0.08x | $47.96 Million |
| Medigen Biotechnology (3176) | $3.54 Billion | -16.06% | 0.36x | $144.62 Million |
| Sagittarius Life Science (3205) | $965.47 Million | -11.83% | 0.10x | $119.60 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.38 Billion | 0.03% | 0.10x | $98.37 Million |
About Apex Biotechnology Corp
Apex Biotechnology Corp. researches, develops, manufactures, and sells home care medical devices by using biosensor technology worldwide. The company offers blood glucose, uric acid, hemoglobin, cholesterol, lactate, HbA1C, and ketone monitoring systems, as well as coagulation and multifunctional self-testing. It also provides pesticide residue check systems; and care management and tele-health s… Read more